company background image
ALM logo

Almirall BME:ALM Stock Report

Last Price

€9.62

Market Cap

€2.0b

7D

-2.4%

1Y

22.9%

Updated

23 Jun, 2024

Data

Company Financials +

ALM Stock Overview

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends1/6

Almirall, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Almirall
Historical stock prices
Current Share Price€9.62
52 Week High€10.08
52 Week Low€7.16
Beta0.38
11 Month Change-0.57%
3 Month Change19.58%
1 Year Change22.94%
33 Year Change-35.82%
5 Year Change-40.76%
Change since IPO-35.87%

Recent News & Updates

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Recent updates

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Is Almirall (BME:ALM) A Risky Investment?

May 16
Is Almirall (BME:ALM) A Risky Investment?

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29
Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01
Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06
Is Almirall (BME:ALM) Using Too Much Debt?

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05
How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15
Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Almirall, S.A. (BME:ALM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 02
Almirall, S.A. (BME:ALM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Would Shareholders Who Purchased Almirall's (BME:ALM) Stock Five Years Be Happy With The Share price Today?

Jan 20
Would Shareholders Who Purchased Almirall's (BME:ALM) Stock Five Years Be Happy With The Share price Today?

Shareholder Returns

ALMES PharmaceuticalsES Market
7D-2.4%-0.1%0.3%
1Y22.9%19.9%16.7%

Return vs Industry: ALM exceeded the Spanish Pharmaceuticals industry which returned 19.9% over the past year.

Return vs Market: ALM exceeded the Spanish Market which returned 16.7% over the past year.

Price Volatility

Is ALM's price volatile compared to industry and market?
ALM volatility
ALM Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement3.1%
10% most volatile stocks in ES Market6.3%
10% least volatile stocks in ES Market0.9%

Stable Share Price: ALM has not had significant price volatility in the past 3 months.

Volatility Over Time: ALM's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19431,904Carlos Gallardo Piquéwww.almirall.com

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
ALM fundamental statistics
Market cap€2.01b
Earnings (TTM)-€38.77m
Revenue (TTM)€915.09m

2.2x

P/S Ratio

-52.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALM income statement (TTM)
Revenue€915.09m
Cost of Revenue€245.20m
Gross Profit€669.89m
Other Expenses€708.66m
Earnings-€38.77m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 22, 2024

Earnings per share (EPS)-0.19
Gross Margin73.21%
Net Profit Margin-4.24%
Debt/Equity Ratio23.9%

How did ALM perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

-97%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.